Institut universitaire en santé mentale de Montréal

BioMark to Collaborate with Astrazeneca, Pfizer Canada and The IUCPQ Foundation in a $3.5m Project to Improve Early Detection of Lung Cancer

Retrieved on: 
Tuesday, November 30, 2021

Yohan Boss at the Quebec Heart and Lung Institute (Institut Universitaire de Cardiologie et Pneumologie du Qubec-Universit Laval - IUCPQ-UL).

Key Points: 
  • Yohan Boss at the Quebec Heart and Lung Institute (Institut Universitaire de Cardiologie et Pneumologie du Qubec-Universit Laval - IUCPQ-UL).
  • The new screening tools will be combining radiomics, genetics and metabolomics biomarkers who will be integrated using artificial intelligence.
  • "When detected early, lung cancer patients have more treatment options and a far greater chance of survival.
  • BioMark is developing proprietary, non-invasive, and accurate liquid biopsy-based cancer diagnostic solutions which can help detect, monitor, and assess treatment for cancer early and cost-effectively.

OpSens Successfully Completes 20-Patient in Human Clinical Study for TAVR Procedure

Retrieved on: 
Tuesday, November 23, 2021

"Structural heart procedures are rapidly growing worldwide, driven by the TAVR procedure and the expansion of its indications.

Key Points: 
  • "Structural heart procedures are rapidly growing worldwide, driven by the TAVR procedure and the expansion of its indications.
  • Initially, the TAVR procedure was only indicated for inoperable patients and then for high-risk surgical patients.
  • Clinical programs like ''PARTNER III'' and ''Evolut Low Risk'', have since shown better or equivalent clinical outcomes in intermediate and low-risk patients.
  • OpSens is also involved in industrial activities in developing, manufacturing, and installing innovative fiber optic sensing solutions for critical applications.

OpSens Successfully Treats First Patients in Human Clinical Study for TAVR Procedure

Retrieved on: 
Wednesday, October 13, 2021

"We are extremely pleased to have commenced this important safety study with the first two patients successfully treated with the SavvyWire.

Key Points: 
  • "We are extremely pleased to have commenced this important safety study with the first two patients successfully treated with the SavvyWire.
  • Structural heart procedures are a rapidly growing market, driven by the TAVR procedure and the expansion of its indications," said Louis Laflamme, President and Chief Executive Officer of OpSens.
  • Initially, the TAVR procedure was only indicated for inoperable patients and then for high-risk surgical patients.
  • Clinical programs like PARTNER or COREVALVE, have since shown better or equivalent clinical outcomes in intermediate and low-risk patients.